A5002815766- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Molecular Biology Techniques and Applications
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- PI3K/AKT/mTOR signaling in cancer
- Nutrition, Genetics, and Disease
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Single-cell and spatial transcriptomics
- Neonatal Respiratory Health Research
- Cancer and Skin Lesions
- Genetic factors in colorectal cancer
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Gene expression and cancer classification
- Cancer-related Molecular Pathways
- Preterm Birth and Chorioamnionitis
- Cancer Cells and Metastasis
- Pregnancy-related medical research
- Urologic and reproductive health conditions
- Multiple and Secondary Primary Cancers
- Genital Health and Disease
Universitair Ziekenhuis Leuven
2018-2023
KU Leuven
2013-2022
Inserm
2019
Immunité et Cancer
2019
Institut Curie
2019
Agendia (Netherlands)
2019
AZ Sint-Jan
2015-2016
Abstract Since a detailed inventory of endothelial cell (EC) heterogeneity in breast cancer (BC) is lacking, here we perform single RNA-sequencing 26,515 cells (including 8433 ECs) from 9 BC patients and compare them to published EC taxonomies lung tumors. Angiogenic ECs are phenotypically similar, while other subtypes different. Predictive interactome analysis reveals known but also previously unreported receptor-ligand interactions between immune cells, suggesting an involvement responses....
Traditional population-based cervical screening programs, based on cytology, have successfully reduced the burden of cancer. Nevertheless limitations remain and new methods are emerging. Despite vaccination against 2 most oncogenic types (HPV 16/18), cancer will to continue as an essential public health strategy. As acquisition HR-HPV infection is critical in progression (pre-)cancerous lesions, recent research has focused detection. The sensitivity HPV testing primary secondary prevention...
Juvenile papillomatosis of the breast, also known as Swiss cheese disease, is a rare and benign proliferative disorder affecting young women. These patients tend to have strong family history cancer. The lesion typically presents localized mass without sharp borders. Clinical presentation resembles that precancerous lesion. For this reason, JP often misdiagnosed in preoperative period. However postoperative histopathological examination reveals distinct microscopic features, such duct...
A previously developed and centrally validated MammaPrint® (MP) BluePrint® (BP) targeted RNA next-generation sequencing (NGS) kit was implemented in two large academic European hospitals. Additionally, breast cancer molecular subtypes by MP BP were compared with immunohistochemistry (IHC). Patients early diagnosed at University Hospitals Leuven Curie Institute Paris prospectively included between September 2017 January 2018. Formalin-fixed paraffin-embedded tissue sections analyzed NGS...
Neratinib is approved based on the phase III ExteNET study in Europe since 2018 to treat adult patients with Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-positive (HR+/HER2+) early-stage breast cancer (eBC) completing adjuvant trastuzumab-based therapy <1 year ago (EU label). A 2017 Early Access Program (EAP) granted neratinib access awaiting product availability. The eBC treatment landscape has evolved ExteNET, and there a need assess safety effectiveness recent...
Abstract Introduction Breast cancer patients with a high-risk tumor (for example Triple Negative Cancer) who achieve pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) have better outcome compared to residual disease at surgery. This study investigated Cancer Free Survival (BCFS) and predictors for distant relapse despite pCR. Methods Monocentric retrospective of 243 consecutive breast achieved pCR (ypT0/is ypN0/N0(i+)) after treatment NACT in UZ Leuven between...
Abstract Background The introduction of multi-gene panel testing in the diagnosis hereditary breast and ovarian cancer (HBOC) has led to an important increase detection predisposition genes other than BRCA1 BRCA2. Methods All individuals who underwent HBOC-testing at our institution since were included (March 2016-August 2017). In this retrospective analysis, BRCA Hereditary Cancer MASTR Plus® is used (Multiplicom, Belgium), with sequencing BARD1, BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, TP53,...
Abstract Palbociclib, a first-in-class CDK 4/6 inhibitor, in combination with letrozole or fulvestrant is now licensed for the first second line treatment of postmenopausal women hormone-sensitive HER-2 negative metastatic breast cancer (MBC), but its activity later lines unknown. In Belgium, compassionate Use Program (CUP) was temporarily established to provide palbociclib after at least 4 systemic MBC. The UZ Leuven Multidisciplinary Breast Center included 82 patients this CUP from...
Abstract Background Many countries restrict patient material exchange to central diagnostic laboratories abroad, limiting access assays like MammaPrint® (MP) and BluePrint® (BP). Both are microarray-based, with MP being prognostic for distant recurrence BP molecular subtyping of breast cancer (Luminal-, HER2-, Basal-type). To increase accessibility, decentralization is required Next Generation Sequencing (NGS) the preferred testing platform given that most have technology in place. The aim...
Abstract Background MammaPrint® (MP) and BluePrint® (BP) are microarray-based tests with MP being prognostic for distant recurrence BP enabling stratification into breast cancer molecular subtypes (Luminal, HER2, Basal-type). Recently, a CE marked targeted RNA Next Generation Sequencing (NGS)-based kit was developed at Agendia validated University Hospitals Leuven Curie Institute Paris. Here we compare subtype defined by immunohistochemistry (IHC) NGS- microarray- based tests. Patients...
Abstract Background In patients with clinically lymph node negative (cN0) early breast cancer (EBC) treated neoadjuvant chemotherapy (NACT), the sentinel biopsy (SLNB) can be performed before or after NACT. We report safety of axillary staging performing SLNB prior to NACT in cN0 EBC and estimate NACT-induced downstaging ypN0 previously NACT-treated cN1 EBC, make an assumption for avoiding dissection (ALND) if was done Patients Methods Monocentric retrospective study consecutive triple...
Background Multigene signatures (MGS) select women with estrogen receptor positive human epidermal growth factor 2 negative (ER+/HER2-) breast cancers where adjuvant chemotherapy (aCT) can be avoided. However, MGS are expensive and not always reimbursed. We investigated the predictive value of five inexpensive statistical models in tumors low or high risk relapse based on change decision to add following results.Patients Methods In this retrospective study, we evaluated patients diagnosed...
Abstract Background Multigene signatures (MGS) select women with estrogen receptor positive human epidermal growth factor 2 negative (ER+/HER2-) breast cancers where adjuvant chemotherapy (aCT) can be avoided. However, MGS are expensive and not always reimbursed. We investigated the predictive value of five inexpensive statistical models in tumors low or high risk relapse based on change decision to add following results. Patients Methods In this retrospective study, we evaluated patients...
Abstract Background Multigene signatures (MGS) select women with estrogen receptor positive human epidermal growth factor 2 negative (ER+/HER2-) breast cancers where adjuvant chemotherapy (aCT) can be avoided. However, MGS are expensive and not always reimbursed. We investigated the predictive value of six inexpensive statistical models in tumors low or high risk relapse based on change decision to add following results. Patients Methods In this retrospective study, we evaluated patients...
Abstract Background: The introduction of multi-gene panel testing and improved awareness under patients physicians has led to an increase individuals with known germline pathogenic variants in hereditary breast ovarian cancer (HBOC) genes. Significant regional differences exist mutational landscape. We aimed report the findings from a large Belgian cohort at risk for HBOC. Methods: All who underwent HBOC Center Human Genetics University Hospitals Leuven since were included (March 2016-April...